Bromocriptine

• Description:

  Bromocriptine is a potent dopamine D2/D3 receptor agonist, which binds D2 dopamine receptor with pKi of 8.05±0.2.

• Product Name Alternative:

  CB-154 (free base)

• UNSPSC:

  12352005

• Hazard Statement:

  H301-H311-H331

• Target:

  Dopamine Receptor

• Type:

  Natural Products

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Bromocriptine.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [H][C@@]12CC3=C (Br) NC4=CC=CC (C1=C[C@@H] (C (N[C@@]5 (C (C) C) C (N6[C@@H] (CC (C) C) C (N7CCC[C@]7 ([C@]6 (O) O5) [H]) =O) =O) =O) CN2C) =C43

• Molecular Formula:

  C32H40BrN5O5

• Molecular Weight:

  654.59

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361-P403+P233-P405-P501

• References & Citations:

  [1]Gardner B, et al. Agonist action at D2 (long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998 Jul;124 (5) :978-84.|[2]Renodon A, et al. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects.FEBS Lett. 1997 Apr 7;406 (1-2) :33-6.|[3]Wynalda MA, et al. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997 Oct;25 (10) :1211-4.|[4]Rana DG, et al. Dopamine mediated antidepressant effect of Mucuna pruriens seeds in various experimental models of depression. Ayu. 2014 Jan;35 (1) :90-7.|[5]Dieb W, et al. Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain. 2016;17:11.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Citation 01:

  Clin Immunol. 2025 Oct 14:281:110604.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Pharmacogn Mag. 2023 Oct 12.|Toxicol Appl Pharmacol. 2024 Apr:485:116876.|Aquaculture. 2025 Apr 15.|bioRxiv. 2025 Oct 13.|BMC Endocr Disord. 2021 Nov 23;21 (1) :235.|Br J Pharmacol. 2021 Sep;178 (17) :3570-3586.|Eur J Integr Med. 2021, 101322.|Eur J Pharmacol. 2023 Jan 5:938:175443.|Int J Mol Sci. 2024 Nov 21;25 (23) :12483.|J Biomol Struct Dyn. 2022;40 (23) :12800-12811.|J Endocrinol Invest. 2025 Jan;48 (1) :67-80.|J Ethnopharmacol. 2021 Jun 12:273:113994.|Nat Commun. 2020 Feb 18;11 (1) :941. |Phytomedicine. 2025 Jun:141:156707.|Sci Adv. 2021 Nov 26;7 (48) :eabj4624.

• CAS Number:

  25614-03-3